Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RSII - 4/20 NEWS COMING. CHART SET TO BREAK OUT.
https://www.facebook.com/RisingBioSciences/posts/984389915071587
$RSII - 4/20 NEWS COMING. CHART SET TO BREAK OUT.
https://www.facebook.com/RisingBioSciences/posts/984389915071587
$RSII - News coming tomorrow. Chart is ready to pop. Load this one.
https://www.facebook.com/RisingBioSciences/posts/984389915071587
Someone wants it lower probably to fill their order. They need to slap the ask
This should be a great week. We are starting to gain momentum. Need more volume. Everyone hold your shares tight
They will when news is released
I’m looking at chart. I believe in the pattern.
4/20 News Coming. 2 Days and we will be +.02
$RSII - BREAKOUT ALERT - 4/20 News Coming.
https://www.facebook.com/RisingBioSciences/posts/984389915071587
RSII should be higher than this. 4/20 Coming. https://www.facebook.com/RisingBioSciences/posts/984389915071587
$RSII - BREAKOUT ALERT - NEWS IN 2 DAYS. https://www.facebook.com/RisingBioSciences/posts/984389915071587
News in 2 days and no hype. What’s going on?
I’ve started the Geron shareholders FB group join here: https://m.facebook.com/groups/2079322655660304
Green is good. May get a little more exciting later
I do want to thank shorts for allowing me to load as much as I can the last few weeks under $4
Not new but updated to confirm Imetelstat still on top of drug pipeline
http://www.investor.jnj.com/_document/johnson-johnson-pipeline-q1-2018?id=00000162-d33e-d077-af7a-fbff592e0000
Imetelstat still listed on top for Oncology as pipeline dug. Updated today
From JnJ: "The U.S. tax legislation passed late last year is creating the opportunity for us to invest more than $30 billion in R&D and capital investments in the U.S. over the next four years, which is an increase of 15%."
Isn’t it already in phase 3?
https://globaltrialfinder.janssen.com/trial/CR107947
Very light volume and more selling today. Thought we would be surging. Oh well
I think we will close green.
Not Looking Good. Need news ASAP
April 26th
April 25th JnJ shareholders meeting. Imetelstat would be more likely mentioned then
nucleardog
Apr 13 09:10 AM
There have been some great articles and posts laying out why the results from the clinical trials are pretty strong and indicate that GERN will be successful. I haven't seen an argument from a more purely logical perspective which doesn't focus too much on the numbers. I will attempt to do this using a poker analogy.
There are 3 players at the table with inside information, if we can get a read on these players then that will give us the upper hand when we make our investment decisions. In other words, we don't necessarily need to know what cards they hold in order to make the right decision. The 3 players are: Geron, JNJ, and the FDA (there is a 4th player aka shortie, but all that guy does is bluff).
The CEO of Geron is Dr. Scarlett. I think a fair description of him would be that he is pretty reserved and conservative when it comes to speaking and making statements about Geron. Let's take a look at the 2016 annual letter to stockholders. He mostly just recites facts, and he uses phrases like "if that occurs" when speaking about whether or not Janssen will move forward with Part 2 of Imerge. He ends the letter with "We look forward to future accomplishments together". This is a somewhat vague statement, and you really have no idea what the time frame is. This is sort of like when someone says "See you around", you have no idea when that will happen. If you look at the 2014 it's also similar, "We appreciate stockholders, employees, physicians and patients, past and present, who have supported Geron and imetelstat over the years. We look forward to your continued support.".
http://bit.ly/2GY9KFa
http://bit.ly/2GVbT8J
Now let's take a look at the 2017 letter. He says stuff like "The proportion of
patients with transfusion-free periods lasting at least 24-weeks for the overall trial population was 16% and for the 13-patient subset it was 31%. These were impressive efficacy outcomes." Using qualitative words like impressive when describing clinical trial results has never been in his repertoire that I am aware of. He also ends the letter with "I would like to thank our stockholders for supporting Geron over the years. We look forward to the outcomes in this important upcoming year." Now he is saying something is going to happen this year, when before he was vague about the time frame. He also says it will be an important year. Again he is using qualitative words that is not the norm for him. This is something people do when they get excited, and I believe this is a tell on his part.
http://bit.ly/2H0Q9EE
I believe JNJ has also tipped their hand. I want to emphasize that a continuation decision by JNJ does not imply that the FDA will approve imetelstat or that the drug will do well in a phase 3. So let's take a look at a recent continuation decision by JNJ for another drug, talacotuzumab. The continuation decision by JNJ in March 2017 netted Xencor a $3.5 payment. We know that talacotuzumab was discontinued about a half year later in October 2017. My point here is that JNJ is willing to take calculated risks and they don't only bet on a sure thing, ie. Geron does not necessarily need the most convincing results for JNJ to make a continuation decision or else that never would have been proceeded with talacotuzumab only to drop it half a year later. If Geron really is skating on thin ice with flimsy data, why wouldn't JNJ just drop them like they did with talacotuzumab and sirukumab? They've already shown they are not afraid of dropping a drug that wasn't performing to their expectations and yet imetelstat is still in the game.
Now let's try to figure out what JNJ thinks of the results that are being delivered. JNJ presented a poster at ASH 2016 that showed that the median os was 7 months. There has been significant doubt shown regarding whether or not the 7 month figure is accurate. However, it seems fair to say that the 7 month figure is what JNJ believes. If you look at the poster, you can see the authors are all JNJ scientists and a 3rd party data analyst. It's not Geron trying to fudge the numbers. Now if JNJ believes the 7 month figure, doesn't it follow that they would be pretty happy with where the median os is currently heading?
http://bit.ly/2JJ2xuK
The FDA is a bit trickier to figure out, however they wrote a letter to the New England Journal of Medicine that was published yesterday that sheds light on how they are going to proceed with a drug like imetelstat. This excerpt is especially on point in regard to imetelstat, "The FDA shows flexibility (described in a statute and regulations) in the design of programs for drugs targeting a serious or life-threatening disease, especially for rare diseases or uncommon cancers, since it may not be feasible or ethical to conduct a randomized trial. This flexibility relates to the diseases being targeted and not the priority designation. Single-group trials with historical controls can provide substantial evidence of effectiveness". This to me is a tell that the FDA will look at imetelstat in a favorable light because after all even with accelerated approval, clinical benefits must be confirmed. It is clear the FDA is comfortable with letting a drug like imetelstat prove itself definitively after accelerated approval happens and also that they don't need a control group to get accelerated approval.
http://bit.ly/2INnzGY;
I have outlined the logical reasons why the inside players have tipped their hands as to what cards they are holding. Of course, please do your own due diligence when making your investment decisions.
I’m watching. Hoping you are right. I’m not so optimistic
If no announcement. Where do you think that will put us
4.20 AH
Let’s close her Green
I Hope they halt this After Hours to announce a Buy-Out at $55 a share
Next 2 Days should get us above $5
$GERN $GERN Why Geron Corporation Stock Is on the Rise Todayhttps://finance.yahoo.com/news/why-geron-corporation-stock-rise-163000581.html